Login to your account
Don’t have an account?
Create a Free Account
An internationally trusted source for clinically focused longevity and healthy ageing research and review
The Lancet Healthy Longevity is a multi-disciplinary journal that publishes clinically focused longevity and healthy ageing research and review. Our broad research remit aims to encompass early-stage clinical research into the mechanisms of ageing at any stage of life through to epidemiological and societal research on changing populations, including clinical trials in all disciplines focused, but not exclusively, on older people, gerontological science, and age-specific clinical guidelines.
We also publish clinical and policy reviews, which aim to shape and contextualise the debate on this fast-growing discipline. The Lancet Healthy Longevity continues in The Lancet Group’s tradition of being a strong advocate for the rights of all people to healthy, fulfilling lives, irrespective of age, and prioritises reports of original research that are likely to change clinical practice or thinking. Cassandra Coburn, Editor-in-Chief, further shares her ambitions for the journal.
We publish a range of content types including Articles, Review, Comment, and Correspondence. We also publish Series that aim to shape and drive positive change in clinical practice and health policy in areas of need in longevity and healthy ageing. Learn more about the types of papers we publish.
The Lancet journals are both a destination for publication and a platform to advance the global impact of research. The Lancet Group cares that your work is highly visible to a global network of researchers, clinicians, industry professionals, policy makers, media outlets, patients, and the wider public, and we work with you and your affiliated institutions to maximise the impact of your research on the world.
- Lancet journals have extensive global reach with more than 36·8 million annual visits and 98·8 million downloaded articles across TheLancet.com and ScienceDirect.
- Lancet Alerts, including our electronic Table of Contents, have over 3·6 million subscriptions.
- Lancet journals have nearly 2·4 million followers on Twitter, Facebook, LinkedIn, Instagram , WeChat, Weibo, and YouTube.
- With over 275 000 annual mentions in news articles, research published in Lancet journals receives regular coverage in influential media such as the Associated Press, BBC, CNN, Financial Times, The Guardian, The New York Times, NPR, and The Washington Post.
- Lancet podcasts receive over 85 000 listens each month.
- Lancet Webinars have been viewed more than 5000 times by audiences in 170 countries.
The Lancet Healthy Longevity is an internationally trusted source of clinical, public health, and global health knowledge, with an Impact Factor of 13·1 (2022 Journal Citation Reports®, Clarivate 2023).
We recognise that the Journal Impact Factor is just one measure of a journal's performance and encourage you to explore journal impact metrics, which provide a means to assess our journals. The Lancet Healthy Longevity is also indexed by the following abstracting and indexing services:
- Crossref
- Directory of Open Access Journals (DOAJ)
- Embase
- Emerging Sources Citation Index (ESCI)
- GoOA (National Science Library, Chinese Academy of Science)
- MEDLINE
- PubMed
- Scopus
Manuscript preparation must adhere to relevant reporting standards on the EQUATOR network website.
Manuscripts must be solely the work of the author(s) stated, must not have been previously published elsewhere, and must not be under consideration by another journal.
Whether you are an existing author or are thinking of submitting to us for the first time, we are committed to supporting you on whatever stage of your publication journey you find yourself.
As trusted sources of information, The Lancet Group sets extremely high standards for publishing, and we are committed to ensuring that our editorial processes meet our standards of excellence. From acceptance of your paper through to publication and beyond, our Editors, Assistant Editors, Illustrators, Production Editors, Journal Managers and Marketing and Communications experts provide guidance to strengthen the accuracy, accessibility, timeliness, and impact of your research.
Lancet journals are signatories of the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals issued by the International Committee of Medical Journal Editors (ICMJE Recommendations) and to the Committee on Publication Ethics (COPE) code of conduct for editors. We follow COPE's guidelines.
The Lancet Healthy Longevity is a gold open access journal. All content, including Reviews and Comments, is published under a gold open access licence, but the article processing charge (APC) only applies to full-length articles that are peer reviewed. All content is immediately and freely available to anyone and published under a Creative Commons license, which enables authors to retain copyright of their work.
To support the costs of publishing including reviewing (first by internal review, and then external peer review), technical copy editing, typesetting and graphics, online hosting, archiving, and promotion, authors who publish OA in our journals pay the APC, upon acceptance. The APC is paid by you, your institutions, or funding bodies. We believe ability to pay should never be a barrier to publication, and there are several options, including waivers and discounts available to authors to support publishing fees.
Explore your options for publishing open access, including information regarding APCs, waivers and discounts, and copyright options.
The Editor-in-Chief is the final arbitrator of all decisions on each of the Lancet journals—for example, the decision to take a paper to peer review, the decision to publish or reject in light of the peer reviewers’ remarks, journal scope and commissioning, consideration of appeals, general enquiries, and editorial priorities at any given time. The Lancet Group does not permit the Editor-in-Chief, or any in-house editors, to submit full-length articles to any of our journals.
Philippa Harris Editor-in-Chief
Following a PhD in molecular parasitology at the National Institute of Medical Research (UK), I completed a postdoctoral position at the Albert Einstein College of Medicine (USA). I began my career in scientific publishing with BioMed Central and was the Editor of BMC Infectious Diseases before joining The Lancet HIV as Deputy Editor in 2018. I joined The Lancet Healthy Longevity as Acting Editor-in-Chief in 2022.
Sophie Raeder, Senior Editor
I completed my PhD in Psychiatry at the Oxford Centre for Human Brain Activity at the University of Oxford (UK). My research investigated attentional biases in anxious adults, in particular comparing biases between young and older adults. I thereafter joined the UCL Unit for Stigma Research as a postdoctoral research fellow. My research interests include anxiety, old age psychiatry, mental health stigma, and developing new methods for improving mental health in vulnerable groups.
If you have additional queries, we will be pleased to help. Please email us directly or at [email protected].
Learn more about the teams and people supporting The Lancet Healthy Longevity.
Our International Advisory Board consists of key opinion leaders and researchers from around the world who lend their expertise to the journal. The Board offer the journal subject, academic, and geographical advice on an ad hoc basis when requested by the editorial team. Board members have no formal involvement in content selection or in any part of the peer review process, nor do they have editorial oversight of any section of the journal. Board members are occasionally invited to peer review individual submissions at the request of the editorial team. Submissions authored by members of the Board are handled solely by The Lancet Healthy Longevity's editors according to our standard peer review processes; these submissions are never discussed by the Board or members thereof.
We are very grateful for their support and advice on editorial matters.
If you need to question an editorial decision, your first step should be to contact the editorial team. If you are not satisfied with our response, your next point of contact is our Ombudsperson whose task is to record and, when required, investigate allegations of editorial maladministration. Our files will be freely open to their inspection, and confidentiality will be respected in all cases. Our Ombudsperson’s remit does not extend to areas normally covered in our correspondence columns—namely, issues of editorial content and editorial policy.